FDA clears Prime Medicine's PM647 in vivo gene-editing therapy for alpha-1 antitrypsin deficiency
What's the deal? On 24 September 2026, Prime Medicine announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for PM647, allowing the company to begin clinical testing in the United States. PM647 is an in vivo Prime Editor — a gene-editing tool that works directly inside the body — being developed for alpha-1 antitrypsin deficiency (AATD), a genetic condition that can destroy the lungs and liver.
How it works and why it matters: AATD happens when a faulty gene fails to produce enough of alpha-1 antitrypsin, a protein that protects the lungs. The shortage leaves patients vulnerable to progressive lung damage and emphysema, often before age 50. PM647 is designed to correct the faulty gene in the liver — where the protein is made — with a single intravenous infusion, using the Prime Editing technology that can rewrite a precise stretch of DNA rather than simply cutting it. The first-in-human Phase 1/2 study will test the therapy in adults with lung-related AATD, with early data expected in 2027.
This is the company's second US IND clearance for an in vivo programme, after PM577a for Wilson disease in 2024, and one of the first attempts to treat AATD at its genetic root.
Read more: Prime Medicine, 24 September 2026